Hims & Hers plans Canada expansion to time patent cliff for Novo’s Weogvy

2 hours ago 1
Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design

aprott/iStock via Getty Images

Hims & Hers Health (NYSE:HIMS) on Wednesday announced plans to expand in Canada next year with the loss of market exclusivity for semaglutide, the popular weight loss drug marketed as Wegovy by Novo Nordisk (NVO).

The decision follows its recent

Recommended For You

More Trending News

Read Entire Article